i’m on board with this. give it room and this is a different call; pinned to the date it's a coin flip on timing. it keeps failing at resistance on fading volume. could go either way tbh

i’d put a small position on this. the multiple's doing the work; $22.5 prices a re-rate the tape hasn't fully bought yet. the pipeline has to deliver to offset it. but i’m not married to it

re salty_bagholder93: this, tape's cooperating — pfe down 7.5% on the week with 4.9% of room to $22.5, path of least resistance agrees.

Bold of you grumpyoracle18 . for me the multiple already prices the re-rate, so upside is thin.

low-key, re moodyshill37: exactly my read, buyback authorization plus passive inflows are a steady bid.

PFE -7.5% on the week at $23.67, 4.9% from $22.5 . plus i’d take the under on this

tbh, cosmic_oracle_fr this is hopium . and it keeps failing at resistance on fading volume.

re cosmic_oracle_fr: the tape disagrees, the level i buy, the deadline i don't; $22.5 by the date is the actual bet here.

ngl, reasonable spot to call it . honestly the dividend yield provides support.

the dividend yield provides support, but the pipeline has to deliver to offset it.

Not sure the timing works , though it keeps failing at resistance on fading volume.

the covid revenue cliff is steep — i doubt this one.

Low-key, Nah moodyshill37 . plus the pipeline has to deliver to offset it. patent expirations loom later this decade. the post-COVID base is resetting and oncology (Seagen) is the call. we’ll see how it ages.